Literature DB >> 19034339

Synergistic effect of methyltetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphism as risk modifiers of pediatric acute lymphoblastic leukemia.

Azza M Kamel1, Heba S Moussa, Gamal T Ebid, Rong R Bu, Kishor G Bhatia.   

Abstract

BACKGROUND AND
PURPOSE: ALL is the most common pediatric cancer. The causes of the majority of pediatric acute leukemia are unknown and are likely to involve an interaction between genetic and environmental factors. Therefore, unfavourable gene-environmental interactions might be involved in the genesis of ALL. The aim of this work was to evaluate, in a case-control study, whether the common polymorphisms in 5, 10-methylenetetrahydrofolate reductase (MTHFR) namely (C677T and A1298C) and methionine synthase (MS) (A2756G) genes may play a role in altering susceptibility to pediatric ALL as individual genes and in combination. PATIENTS AND METHODS: DNA of 88 ALL patients (age < or = 18 years) and 311 healthy control subjects was analyzed for the polymorphisms of MTHFR and MS genes using PCR-RFLP method.
RESULTS: The frequencies of the wild types of MTHFR 677CC, MTHFR 1298AA and MS 2756AA, the homozygous genotypes of MTHFR 677TT, MTHFR 1298CC and MS 2756GG and heterozygous genotypes of MTHFR 677CT and MS 2756AG showed no statistically significant differences between patients and controls. The frequency of the MTHFR 1298AC heterozygous genotype was 25% among patients compared to 45.0% among controls; the difference was found to be statistically significant (p value =0.001, O.R=0.382 &amp; 95% C.I=0.222-0.658). The frequency of the MTHFR1298AC heterozygous genotype plus 1298CC homozygous genotype was 34% among patients compared to 54.3% among controls and the difference was statistically significant (p value =0.001). A synergistic effect of 677CT and1298AC (CTAC) was observed, (p value=0.002) with 3.65 fold protection (OR 0.273 &amp; 95% C.I=0.155-0.9) compared to 2.6 folds for MTHFR 1298AC alone. This protective effect of CTAC polymorphism was abolished when combined with MS 2756AA or AG.
CONCLUSION: The present study provided further evidence for the protective role of MTHFR 1298AC mutant alleles in acute lymphoblastic leukemia in children (2.6 fold protection). This suggests that folate and methionine metabolism play an important role in the pathogenesis of pediatric ALL. In contrast to the main bulk of literature, we did not find any protective role of either MTHFR C677T or MS A2756G polymorphisms. This may reflect the ethnic variation in both the polymorphism frequencies, variation in plasma level of folate, in addition to the possible role of gene-environment interaction mainly dietary availability of folate. The synergistic effect of MTHFR 1298AC and 677CT and its abolishment by MS 2756AA or AG further emphasizes that the interaction of genes, rather than the polymorphism in any single one, determines risk susceptibility to disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19034339

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  13 in total

Review 1.  Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.

Authors:  Jayaram Vijayakrishnan; Richard S Houlston
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

2.  Genetic variants in the folate pathway and risk of childhood acute lymphoblastic leukemia.

Authors:  Catherine Metayer; Ghislaine Scélo; Anand P Chokkalingam; Lisa F Barcellos; Melinda C Aldrich; Jeffrey S Chang; Neela Guha; Kevin Y Urayama; Helen M Hansen; Gladys Block; Vincent Kiley; John K Wiencke; Joseph L Wiemels; Patricia A Buffler
Journal:  Cancer Causes Control       Date:  2011-07-12       Impact factor: 2.506

3.  MTHFR Gene Polymorphisms and the Risk of Acute Lymphoblastic Leukemia in Adults and Children: A Case Control Study in India.

Authors:  Sudha Sazawal; Rekha Chaubey; Pawandeep Kaur; Sunita Chikkara; Bijender Kumar; Sameer Bakshi; L S Arya; Vinod Raina; Alakananda Das Gupta; Renu Saxena
Journal:  Indian J Hematol Blood Transfus       Date:  2013-08-28       Impact factor: 0.900

4.  Lack of Impact of the A1298C MTHFR on the Risk of Childhood Acute Lymphoblastic Leukemia: Evidence from a Meta-analysis.

Authors:  Rim Frikha
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-26       Impact factor: 0.900

Review 5.  A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.

Authors:  Muzeyyen Izmirli
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

6.  MTHFR gene polymorphism in acute lymphoblastic leukemia among North Indian children: a case-control study and meta-analysis updated from 2011.

Authors:  Nirmalya Roy Moulik; Farah Parveen; Archana Kumar; Shally Awasthi; Suraksha Agrawal
Journal:  J Hum Genet       Date:  2014-06-12       Impact factor: 3.172

7.  The association of methylenetetrahydrofolate reductase genotypes with the risk of childhood leukemia in Taiwan.

Authors:  Jen-Sheng Pei; Chin-Mu Hsu; Chia-Wen Tsai; Wen-Shin Chang; Hong-Xue Ji; Chieh-Lun Hsiao; Chia-En Miao; Yuan-Nian Hsu; Da-Tian Bau
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

8.  Methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia-evidence from an updated meta-analysis including 35 studies.

Authors:  Haigang Wang; Jiali Wang; Lixia Zhao; Xinchun Liu; Wenjie Mi
Journal:  BMC Med Genet       Date:  2012-09-04       Impact factor: 2.103

9.  Influence of Methylenetetrahydrofolate Reductase C677T, A1298C, and G80A Polymorphisms on the Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.

Authors:  Dayse Maria Vasconcelos de Deus; Elker Lene Santos de Lima; Rafaela Maria Seabra Silva; Edinalva Pereira Leite; Maria Tereza Cartaxo Muniz
Journal:  Leuk Res Treatment       Date:  2012-10-17

10.  Association between MTHFR C677T polymorphism and risk of acute lymphoblastic leukemia: a meta-analysis based on 51 case-control studies.

Authors:  Su-yi Li; Jie-yu Ye; En-yu Liang; Li-xia Zhou; Mo Yang
Journal:  Med Sci Monit       Date:  2015-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.